Laurus Labs Ltd.

NSE: LAURUSLABS  SECTOR: Pharmaceuticals & Drugs

1327.1
+35.7 (2.76%)

Price Summary

Today's High

₹ 1359.6

Today's Low

₹ 1275

52 Week High

₹ 1549.8

52 Week Low

₹ 303.7

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.

Company Essentials

Market Cap

14226.37915729 Cr.

Enterprise Value

15254.19815729 Cr.

No. of Shares

10.7198999 Cr.

P/E

34.8

P/B

7.21

Face Value

₹ 10

Div. Yield

0.19%

Book Value (TTM)

₹  184.1241

CASH

0.933 Cr.

DEBT

1028.752 Cr.

Promoter Holding

32.04%

EPS (TTM)

₹  38.1344

Sales Growth

25.0961474821881%

ROE

15.7238760952888 %

ROCE

14.4063253302478 %

Profit Growth

9.54647905953345 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1w1m3m6m1Yr3Yr5Yr

* Prices are based on daily market changes.

Valuation Chart 1w1m3m6m1Yr3Yr5Yr

* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

Sales Growth (in Cr.)

1 Year25.1%
3 Year13.92%
5 Year16.1%

Profit Growth (in Cr.)

1 Year181.12%
3 Year10.12%
5 Year29.43%

ROE%

1 Year15.72%
3 Year11.33%
5 Year14.48%

ROCE %

1 Year14.41%
3 Year12.09%
5 Year14.02%

Debt/Equity

0.568002226177909

Price to Cash Flow

41.28

Interest Cover Ratio

4.47130446678979

CFO/PAT (5 Yr. Avg.)

1.8947159400119

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2020 32.04 45.22
Dec 2019 32.58 32.27
Sep 2019 32.73 31.69
Jun 2019 32.82 31.46
Mar 2019 32.77 30.22
* Figures given above are % of equity capital

 Strengths

  • Company’s PEG ratio is 0.193481433014935.
  • The company has a good cash flow management; CFO/PAT stands at 1.8947159400119.

 Limitations

  • The company has shown a poor revenue growth of 13.9235931343773% for the Past 3 years.
  • Promoter pledging has increased from 32.04% to 45.22% in 1 quarter.
  • Tax rate is low at 12.2946512437517.
  • Promoter pledging is high as 45.22%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020
Net Sales 541.26 705.86 720.99 829.23 970.41
Total Expenditure 457.53 566.76 569.94 636.42 705.83
Operating Profit 83.74 139.1 151.05 192.81 264.58
Other Income 4.48 1.28 1.97 1.63 6.48
Interest 22.01 25.04 20.38 20.29 14.56
Depreciation 44.95 47 46.72 45.19 47.66
Exceptional Items 0 0 0 0 0
Profit Before Tax 21.26 68.35 85.93 128.95 208.84
Tax 4.23 8.81 7.97 16.42 50.06
Profit After Tax 17.03 59.54 77.95 112.53 158.78
Adjusted EPS (Rs) 0.16 0.56 0.73 1.05 1.49

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 1774.64 1891.92 2026.84 2236.15 2797.34
Total Expenditure 1402.6 1478.1 1618.1 1884.69 2227.1
Operating Profit 372.04 413.82 408.75 351.46 570.23
Other Income 4.35 31.94 28.84 16.13 5.81
Interest 111.04 96.97 75.44 85.83 87.71
Depreciation 85.79 103.78 121.23 160.53 183.85
Exceptional Items 0 0 0 0 0
Profit Before Tax 179.56 245.02 240.91 121.22 304.48
Tax 34.9 45.06 67.77 26.23 37.44
Net Profit 144.65 199.96 173.14 94.99 267.05
Adjusted EPS (Rs.) 91.74 18.74 16.33 8.92 24.98

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 82.38 105.76 106.03 106.44 106.91
Total Reserves 789.99 1249.82 1407.27 1484.46 1708.89
Borrowings 459.74 122.39 141.66 258.66 165
Other N/C liabilities -31.63 13.78 36.15 40.43 52.08
Current liabilities 873.48 1117.34 1268.02 1379.44 1636.72
Total Liabilities 2173.96 2609.09 2959.12 3269.43 3669.6
Assets
Net Block 1013.95 1193.26 1447.69 1598.99 1694.18
Capital WIP 69.6 143.26 163.18 107.15 66.53
Investments 26.12 50.53 51.74 58.32 58.32
Loans & Advances 28.27 25.45 27.87 24.03 39.42
Other N/C Assets 39.02 40.3 39.47 47.13 26.51
Current Assets 996.99 1156.31 1229.16 1433.81 1784.65
Total Assets 2173.96 2609.09 2959.12 3269.43 3669.6
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit Before Tax 179.56 245.02 240.91 121.22 304.48
Adjustment 200.11 195.57 208.04 242.18 288.19
Working Capital Changes -149.19 -69.6 -18.48 -44.89 -208.55
Tax Paid -33.3 -50.11 -61.86 -25.34 -39.45
Operating Cash Flow 197.17 320.88 368.6 293.17 344.67
Investing Cash Flow -314.61 -281.77 -417.48 -256.58 -216.83
Financing Cash Flow 90.18 -47.31 48.99 -36.93 -127.47
Net Cash Flow -27.25 -8.21 0.12 -0.35 0.37

Corporate Actions

Ratings & Research Reports

Company Presentations

Company News

Laurus Labs Stock Price Analysis and Quick Research Report. Is Laurus Labs an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Laurus Labs and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 344.67 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Laurus Labs has a Debt to Equity ratio of 0.568002226177909 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Laurus Labs , the EPS growth was 179.865320619839 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Laurus Labs has OPM of 20.3848305619456 % which is a good sign for profitability.
     
  • ROE: Laurus Labs have a average ROE of 15.7238760952888 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Laurus Labs

X